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Abstract Heart disease is the number one killer of women.
Although there are many similarities between men and wom-
en, the evolving understanding of ischemic heart disease in
women allow us to emphasize the important differences that
need to be recognized. These differences, including symptoms
at presentation, importance of particular risk factors, patho-
physiology of disease, and treatments/outcomes, will be
discussed in this review.
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Introduction
Women in the USA are more likely to die of cardiovascular
disease (CVD) than any other cause [1••]. In fact, cardiovas-
cular disease claims the life of a woman every minute [1••].
The statistics are staggering; however, almost 50 % of white
women and three fourths of Hispanic and black women are
still unaware that this is their greatest risk [2].
Among cardiovascular diseases, coronary heart disease
(CHD) makes up the majority of events for both men and
women below 75 years of age [1••]. The incidence of CHD
in women lags behind men by 10 years, suggesting a protec-
tive effect in women that is lost with advanced age, particu-
larly after the onset of menopause. The overall incidence of
CHD is lower in women; however, across all age strata, a
myocardial infarction (MI) is more likely to be fatal in women,
particularly in younger women (under 55 years of age) [1••].
Although the overall trends suggest a decrease in incident
CHD events and CHD-related deaths over the past 20–
25 years in both men and women, the only exception is youn-
ger women (35–44 years of age) for whom the mortality has
increased [3].
Previously it was assumed that heart disease in women was
the same as in men, and the underrepresentation of women in
research studies prevented any alternate sex-specific conclu-
sions. With the emergence of new sex-specific studies and
data, the landscape of heart disease is changing.We now know
that certain risk factors are stronger predictors of heart disease
in women, there are sex differences in symptoms, and there
are differences in the underlying pathophysiology. With the
new understanding of the pathophysiologic differences come
changes in diagnostic testing and treatment strategies.
CHD is traditionally characterized by obstructive athero-
sclerosis in the epicardial coronary arteries resulting in ische-
mia or decreased myocardial blood flow. However, with the
recognition that there are a variety of disorders that result in
ischemia and ischemic symptoms in women, not just coronary
heart disease, the more-inclusive term ischemic heart disease
(IHD) is considered fitting for this discussion [4]. IHD is a
broader term that encompasses any disorder or disease that
results in myocardial ischemia; this includes Cardiac Syn-
drome X, a term used to describe patients with symptoms
and evidence of ischemia but no obstructive coronary artery
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disease [5] and is noted to be more common in women. More
recently, this syndrome has been labeled as female-specific
IHD.
The following review article will discuss the sex differ-
ences in IHD with a focus on the pathophysiology, treatment,
and outcomes.
Symptoms/Clinical Presentation
Angina pectoris is the most common symptom of myocardial
ischemia. The description of Btypical^ angina was based the
presence of classic characteristics of obstructive coronary dis-
ease which included retrosternal chest pressure, exacerbation
with activity, and relief with rest or nitroglycerin, defined in a
population of predominantly men. Of note, other causes of
myocardial ischemia may not present with the same charac-
teristic presentation, for example, patients with coronary va-
sospasm often report pain at rest. The distinction of Btypical^
vs. Batypical^ angina, based on the number of classic charac-
teristics present, was used by Diamond and Forrester to help
determine the pretest probability of atherosclerotic disease [6].
More recently, the term Batypical angina^ is often used when
describing symptoms in women since some women can have
prodromal symptoms of shortness of breath, fatigue, and
weakness with ischemia [7] or other nonclassic descriptions
of pain. However, even thoughwomen are more likely to have
atypical symptoms when compared to men, the most common
presentation in acute coronary syndrome is still typical angina
[8]. In a study evaluating anginal symptoms in men and wom-
en with confirmed obstructive coronary artery disease, there
was no difference in the presenting symptoms [9]. In general,
women have a higher prevalence of angina than men [10] and
more functional impairment from the pain. Interestingly, even
when typical angina is present, women are less likely to have
any evidence of obstructive CAD when angiography is per-
formed [11]. In women with signs and symptoms of IHD yet
without obstructive CAD, the majority will have repeated ep-
isodes of chest pain requiring hospitalization and repeat test-




The absence of traditional cardiac risk factors in midlife is
associated with a low lifetime risk of heart disease [13•]. How-
ever, by the age of 55, a majority of women have at least one
major risk factor putting them at an increased lifetime risk of
cardiovascular disease [13•]. Traditional cardiac risk factors
play a key role in the development of heart disease in women
and men, but the prevalence of certain risk factors differ be-
tween the sexes and some are stronger predictors of heart
disease in women. Women have lower total cholesterol levels
than men until after the fifth decade of life, thereafter their
values are greater [14]. In general, high-density lipoprotein
cholesterol (HDL-C) levels are higher in women than in
men, but decrease during the menopause transition likely
due to hormonal changes [15]. In addition to dyslipidemia,
postmenopausal women also have a clustering of other risk
factors including obesity and hypertension that could be relat-
ed to gender-specific metabolic differences exacerbated by
hormonal imbalances [14]. Diabetes, metabolic syndrome, hy-
pertension, obesity, and hypertriglyceridemia are all stronger
risk factors for ischemic heart disease in women than men
[16–20]. A recent meta-analysis reported that women with
diabetes had a 40 % greater risk of incident CHD compared
withmenwith diabetes [17]. In fact, the presence of diabetes is
thought to take away the relative protection from ischemic
heart disease in young women [14].
Even though there is a lower prevalence of smoking among
women than men (15.9 % vs. 20.5 %) (1), smoking confers a
higher risk of ischemic heart disease in women. In fact, for a
woman, the risk of CHD mortality from cigarettes is equiva-
lent to the risk associated with weighing ~42 kg more than her
nonsmoker counterpart [14]. A recent meta-analysis demon-
strated a 25 % higher relative risk of heart disease in women
smokers compared to men [21].
There is increasing recognition of the importance of life-
style on ischemic heart disease. In a recent study evaluating
young women without underlying CVD disease or CV risk
factors, it was noted that 73 % of CHD cases and 46 % of
CVD risk factor cases were attributable to a poor lifestyle
[22••]. This emphasizes the importance of primordial preven-
tion with education and lifestyle counseling at a young age.
Physical activity and inactivity are both important consid-
erations. A recent study found that after the age of 30, the
population risk of heart disease attributable to physical inac-
tivity outweighed all other risk factors in women [23]. On the
other end of the spectrum, exercise capacity has a strong and
independent positive association with cardiovascular and all-
cause mortality [24]. The adjusted hazard ratio for every 1-
MET decrement in exercise capacity is 1.20 [25].
Nontraditional Risk Factors
Psychosocial factors are known to be associated with an in-
creased incidence of IHD as well as recurrent CV events in
patients with established disease [26] and can prevent individ-
uals from adopting recommended lifestyle changes [27]. Psy-
chosocial problems such as depression are twice as common
in women than in men [28]. For women, family conflicts and
obligations, depression and anxiety are all associated with
increased risk of heart disease whereas for men, work
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obligations and hostility are more commonly associated with
IHD risk [29]. The differential impact of mental stress on
women compared to men was demonstrated in a recent study
in post-MI patients aged 38–60 years, younger women (those
less than 50 years of age) had increased evidence of mental
stress-induced myocardial ischemia as determined by the sum
difference score (SDS) on technetium-99m perfusion imaging
when compared to young men. There was no difference seen
with exercise-induced ischemia or in the older subjects (those
>50 years of age) [30].
Inflammatory markers such as high-sensitivity C-reactive
protein (hs-CRP) can be used in addition to traditional cardiac
risk factors for further risk stratification in men and women.
An elevation is associated with a greater risk of IHD even
when accounting for traditional risk factors. High-sensitivity
CRP is consistently higher after puberty in women [31] and
has been shown to vary with levels of estrogen in postmeno-
pausal women [32]. It has also been demonstrated to help
stratify higher risk women with metabolic syndrome. In one
study of women with metabolic syndrome [33], those with hs-
CRP >3.0 mg/l had twice the risk of future cardiovascular
events compared to those with hs-CRP <3.0 mg/l.
Autoimmune disorders characterized by chronic inflam-
mation such as systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA) primarily affect women and sup-
port the theory that inflammation may be associated with
atherosclerosis. These individuals often manifest ischemic
heart disease at an earlier age and have a rapid progression
of atherosclerosis [34]. Young women with SLE are 50
times more likely to have an acute MI than women of the
same age without it [35].
Sex-Specific Risk Factors
As mentioned earlier, women have a 10-year relative delay
in the clinical expression of IHD that is not completely
understood. Clinicians suspect that the delay is due to the
protective effects of estrogen during a woman’s reproductive
years, since estrogen has anti-atherosclerotic and anti-
inflammatory effects [36], as well beneficial effects on lipids
and endothelial vasomotor function [37]. However, despite
making physiologic sense, hormone replacement therapy as
a preventive measure for women has not proven to be effec-
tive for primary or secondary prevention of cardiovascular
disease [38, 39].
There is increasing recognition of pregnancy-related com-
plications such as preeclampsia, gestational diabetes, and
gestational hypertension as being risk factors for ischemic
heart disease. In fact, women with a history of preeclampsia
have twice the risk of cardiovascular disease and venous
thromboembolism in the decade following their pregnancy
[40] as well as an increased risk of chronic kidney disease
and diabetes mellitus [41]. Recently, there have also been
associations reported between parity and heart disease. Mul-
tiple pregnancies as well as recurrent pregnancy losses have
been associated with increased risk of future ischemic heart
disease [42, 43]. Interestingly, a recent cohort study demon-
strated that women who successfully used fertility therapy to
get pregnant did not have an increased risk of cardiovascular
disease in the next 10 years, but rather there was a signal
toward benefit [44].
Ovulation dysfunction has also been associated with infer-
tility and increased risk of IHD in women. Women with poly-
cystic ovarian syndrome (PCOS) have an increased preva-
lence of glucose intolerance, metabolic syndrome, and diabe-
tes [45], which are associated with increased risk of IHD.
Women undergoing cancer treatment such as radiation or
chemotherapy are at increased risk of heart disease. There is a
linear relationship between the dose of ionizing radiation ex-
posure during breast cancer radiotherapy and the risk of major
coronary events in women [46]. As cancer therapy improves,
this risk is of increasing importance since survivors of breast
cancer are more likely to die of CVD than breast cancer. There
may be ways to minimize the risk associated with radiothera-
py by adjusting dosage and patient position [47•].
Risk Prediction
Risk prediction models, such as the Framingham risk score,
are largely age-dependent and only forecast 10-year risk. This
can result in underestimation of the lifetime risk for women,
especially young women. The AHA BEffectiveness-Based
Guidelines for Prevention of Coronary Artery Disease in
Women – 2011 Update^ suggested a risk prediction model
that relies on risk factor burden, including sex-specific risk
factors, rather than age to assess a woman’s risk, and stressed
the importance of taking a pregnancy history as part of the
initial patient evaluation [48]. The atherosclerotic cardiovas-
cular disease (ASCVD) risk score is a new risk assessment
tool that includes stroke in the outcome. This is especially
important when assessing risk in women. The calculator helps
clinicians determine the need for cholesterol reducing therapy
and also provides a lifetime risk assessment for patient educa-
tion. The calculator incorporates the traditional risk factors
used in the Framingham risk score but does not incorporate
sex- specific risk factors as discussed above, so these need to
be evaluated and considered separately.
Differences in the Cardiovascular System
Although the overall coronary vasculature is similar, there are
notable sex differences in the cardiovascular system. Women
have smaller left anterior descending artery and right coronary
artery diameters than men as assessed by computed tomogra-
phy [49]. It has also been established that overall women have
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less atheromatous burden than men. Interestingly, this differ-
ence is most significantly seen in the coronary vascular bed
and is absent in the aorta and peripheral vasculature [50].
There are also sex differences in the autonomic nervous sys-
tem control of the cardiovascular system [51]. Women have
more parasympathetic activity than men, who have higher
sympathetic activity [52]. These differences are thought to
be mediated by a variety of factors including hormonal differ-
ences [52], fat distribution [53], and psychological disorders
[54]. An imbalance in the autonomic regulation in postmeno-
pausal women has been implicated for takotsubo, a stress-
mediated cardiomyopathy affecting predominantly women,
as well as female-specific ischemic heart disease.
Proposed Pathophysiology of Ischemic Heart Disease
The presumption that ischemic heart disease is the same in
men and women was challenged by the Coronary Artery Sur-
gery Study (CASS) which was a large, multicenter study that
involved close to 25,000 patients of which a quarter were
women. A substantial number of women referred for angiog-
raphy did not have evidence of CAD, but many had positive
exercise treadmill stress tests with evidence of ischemia.
Based on these data, one study reported that 53 % of women
vs. 12 % of men had false-positive stress tests [55], implying
decreased sensitivity of the exercise treadmill test in women.
However, recently, it has been suggested that angiography
may be an imperfect gold standard for assessing ischemic
heart disease, and these Bfalse-positive^ tests are evidence of
myocardial ischemia in part of the coronary vasculature not
visualized by angiography [56].
The coronary arterial system is a continuous network made
of functionally distinct vessel segments of decreasing size.
The initial large epicardial coronary arteries, which measure
anywhere from 500 μm to 2–3 mm, are followed by the
prearterioles which measure 100 to 500 μm and lead to the
intramural arterioles with diameters less than 100 μm. The
epicardial arteries have a primary capacitance function with
minimal resistance to coronary flow. Whereas, the arterioles
have a fundamental role in coronary blood flow regulation by
matching myocardial oxygen demand with blood supply via
changes in resistance and dilation [57].
The underlying pathophysiology of ischemic heart disease
can differ depending on the portion of the coronary vascula-
ture affected, whether it is the large epicardial vessels or the
smaller microvasculature (Fig. 1). Coronary artery disease,
coronary vasospasm, and coronary artery dissection are all
causes of IHD that primarily affect the epicardial coronary
arteries. In contrast, microvascular dysfunction refers to dys-
function in the smaller coronary arterioles which can cause
chronic ischemia, acute myocardial infarction, or stress-
mediated cardiomyopathy
Epicardial Coronary Arteries
Typically, coronary artery disease is caused by atherosclerosis
in the epicardial coronary arteries. Obstruction to flow occurs
either by gradual atherosclerosis accumulation or by plaque
rupture resulting in occlusive thrombus formation. The utili-
zation of coronary angiography for the diagnosis relies upon
luminal obstruction resulting in contrast-void areas during
angiography.
Even though a large number of women have obstructive
atherosclerosis as a cause of ischemic heart disease, a substan-
tial number of women do not. The absence of obstructive
disease is identified in up to one third of women during a
myocardial infarction [58] and close to two thirds of women
being evaluated for ischemic chest pain [59]. Men also have
nonobstructive disease on presentation, but the incidence is
much lower [58].
Imaging techniques, such as intravascular ultrasound
(IVUS) and optical coherence tomography (OCT) have
allowed for visualization of the vessel wall and a deeper un-
derstanding of the subtle differences in the pathophysiology
which were previously invisible on traditional angiography. In
a prospective study of women with a myocardial infarction
and nonobstructive disease on angiography (defined as <50 %
stenosis in all major vessels), 29 % were noted to have evi-
dence of plaque rupture and 12 % had plaque erosion with
presumed distal embolization as evidenced by myocardial
edema on MRI [60]. The term plaque disruption is a compre-
hensive term used to incorporate any cause of vessel wall
disruption whether it is due to plaque rupture or plaque ero-
sion. Plaque erosions are more commonly seen in women and
younger individuals [61].
Coronary vasospasm has also been implicated as a cause of
myocardial ischemia or injury in the absence of obstructive
coronary artery disease. Although, coronary spasms usually
occur in the epicardial vessels, coronary microvascular spasm
can also occur [62]. Its pathogenesis is likely multifactorial
involving smooth muscle hyperreactivity, endothelial dys-
function, as well as environmental factors such as smoking
or alcohol consumption [63]. Focal vasospasm has been asso-
ciated with atherosclerotic lesions with normal coronary flow
reserve (CFR) whereas diffuse vasospasm has been associated
with significantly reduced CFR suggesting a component of
coronary microvascular dysfunction [63]. Coronary vaso-
spasm is difficult to confirm on angiography and often re-
quires provocative testing with acetylcholine or ergonovine
due to the transient nature of the disease.
Lastly, spontaneous coronary artery dissection (SCAD) is
an important cause of ischemic heart disease, especially in
young women. In a report containing the largest series of
patients with spontaneous coronary artery dissection and no
atherosclerosis, the authors reported a large female predomi-
nance (82 % of the cases were women) with a 10-year major
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adverse cardiac event rate of up to 47 %. The LAD was the
most frequent vessel affected and fibromuscular dysplasia was
noted in half of the femoral angiograms done [64].
Coronary Microvasculature
Coronary microvascular dysfunction (CMD) refers to dys-
function of the coronary arterioles measuring <500 μm in
diameter which includes the prearterioles and intramuscular
arterioles [57]. These arterioles are too small to be visualized
by angiography and thus their function cannot be assessed by
this traditional method. It is thought that microvascular dys-
function is the result of impaired relaxation or increased sen-
sitivity to vasoconstriction which results in inappropriate
myocardial blood regulation. CMD is highly prevalent in
women with chest pain without obstructive disease. In fact,
in the Women’s Ischemia Syndrome Evaluation (WISE)
study, approximately half of the women with chest pain and
ischemia without obstructive CAD had evidence of microvas-
cular dysfunction [65]. Although microvascular dysfunction
has currently been implicated as a common cause of chest pain
in the absence of obstructive disease in women, whether this is
a sex-specific phenomenon is still debated. Takotsubo, a
stress-mediated cardiomyopathy which disproportionately af-
fects older women, has recently been associated with micro-
vascular dysfunction [66]. Additional evidence that microvas-
cular dysfunction may be a problem that disproportionately
affects women comes from the ARIC study where retinal ar-
tery narrowing was shown to be a marker of microvascular
disease and predicted heart disease in women but not men
[67]. The remaining discussion on diagnostic testing, manage-
ment, and outcomes will focus on epicardial atherosclerotic
disease and microvascular dysfunction as the cause of
nonobstructive disease.
Diagnostic Testing
The diagnostic testing for ischemic heart disease has histori-
cally been the same for men and women. The testing modal-
ities can be divided into those that diagnose anatomical dis-
ease vs. those that diagnose functional ischemia. Anatomical
disease can be evaluated using CT-angiography, MRI, or in-
vasive angiography. Functional ischemia can be assessed by a
variety of different stress tests as well as fractional flow re-
serve (FFR) measurements in the cardiac catheterization lab-
oratory. Exercise treadmill testing has been reported as having
a high false-positive rate and thus lower sensitivity in women.
However, there is a shift in thinking that these may not be
false-positive tests but rather evidence of ischemia due to mi-
crovascular dysfunction rather than epicardial coronary ob-
struction [68••]. Other prognostic tools include the Duke
treadmill score which incorporates exercise time, ST-
segment deviation, and angina score into an equation to help
Fig. 1 Mechanisms for ischemic heart disease in women. *Plaque disruption denotes plaque rupture or plaque erosion [60]. ** Adapted with permission
from Oxford University Press and the European Society of Cardiology [105]
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predict risk of CAD: it is a better predictor of significant CAD
in women than men [69]. In addition, exercise capacity is a
powerful predictor of CAD. A nomogram has been
established defining age-predicted exercise capacity for wom-
en [70]. The inability to achieve 85 % of age-predicted fitness
level or achieving less than 5METs is associated with a higher
risk of MI and all-cause mortality [70, 71].
The interest in evaluating microvascular dysfunction in
women has brought to the forefront specific diagnostic ma-
neuvers to assess the health of the coronary microvascular
circulation. These include coronary reactivity testing (CRT)
during cardiac catheterization with adenosine and acetylcho-
line to help diagnose coronary microvascular dysfunction and
dist inguish between endothelium-independent or
endothelium-dependent dysfunction, respectively. The phar-
macologic agents are used to induce a hyperemic state.
CMD is defined as coronary volumetric blood flow increases
of less than 2.5 times baseline flow during maximal hyper-
emic stimuli [72].
In addition, noninvasive techniques are being tested to help
make the diagnosis. Women with confirmed microvascular
dysfunction by CRT had decreased myocardial perfusion re-
serve index on cardiac MRI in response to adenosine [73].
Stress cardiac magnetic resonance (CMR) imaging is gaining
interest. Women with chest pain and nonobstructive CAD
who underwent adenosine CMR were found to have suben-
docardial ischemia more frequently compared to control sub-
jects [74]. Lastly, positron-emission tomography (PET) can be
used to assess coronary flow reserve as measured by myocar-
dial blood flow at peak hyperemia over myocardial blood flow
at baseline. The diagnostic and prognostic significance of the-
se tests are still being explored.
When choosing a diagnostic test, there are sex-specific
concerns that need to be considered such as the patient’s age
and radiation exposure given the association between cumu-
lative exposure and cancer risk in young women [68••]. The
new noninvasive stress testing guidelines emphasize this con-
cern and list expected radiation exposure for each test to help
guide clinicians [68••].
Management of Ischemic Heart Disease
Epicardial Coronary Atherosclerosis
Even though the current treatment of coronary artery disease
is similar for men and women, women are less likely to re-
ceive guideline-based therapy for the treatment of risk factors
[75] and secondary prevention for known coronary artery dis-
ease [76, 77]. These include medications such as antiplatelet
therapy, statins, beta blockers, and angiotensin-converting
enzyme inhibitors (Table 1). In addition, after disease has been
diagnosed, women are consistently referred less often to car-
diac rehabilitation [78, 79] despite the known benefits. Re-
cently, there has been increasing research into sex-related dif-
ferences in the efficacy of traditional treatments. Aspirin, for
unclear reasons, is more effacious for the primary prevention
of myocardial infarction in men but stroke in women. Also,
one study showed that guideline-based statin therapy resulted
in greater atheroma regression for women than men [80].
Coronary Vasospasm
Calcium channel blockers (CCB) are the established therapy
for coronary vasospasm in addition to long-acting nitrates
which can be used alone or as additive therapy to CCB
(Table 1). Magnesium may have a role in acute therapy as
well as prevention [81]. More invasive strategies such as per-
cutaneous coronary intervention (PCI) and coronary artery
bypass grafting are usually only for patients who are refractory
to medical therapy [81].
Coronary Artery Dissection
The treatment for coronary artery dissection remains empirical
and controversial. The overall medical treatment for SCAD is
similar to that recommended for patients with ACS (Table 1).
However, the safety and efficacy of these medications for this
specific indication have not been thoroughly evaluated. In
fact, in one registry, statin therapy was associated with in-
creased risk of recurrent SCAD [64]. This underscores the
need for additional data. Traditionally, an invasive approach
is taken with these patients since they often present with acute
coronary syndrome; however, some are now recommending a
more conservative initial approach due to the high rate of
technical failure [82, 83]
Microvascular Disease
The lack of appropriate treatment and inadequate use of sec-
ondary prevention strategies are exacerbated in patients with-
out obstructive coronary disease [84], especially in women
[85]. This is in part to the limited understanding of the disease
process. In those women who are treated for female-specific
ischemic heart disease, the understanding of the pathophysi-
ology behind microvascular dysfunction has helped the devel-
opment of a variety of treatment options. β-blockers improve
anginal symptoms as well as functional capacity. They are
more effective than channel blocker and nitrates [86] and are
considered the first line of treatment. The third-generation beta
blockers, nebivolol and carvedilol, also have endothelium-
dependent vasodilating properties which may make them
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more effective than traditional β-blockers [87]. Statins and
ACE-I have been shown to improve endothelial dysfunction
[88, 89]. A newer agent, ranolazine, has recently been shown
to improve physical functioning, angina symptoms, and qual-
ity of life in women with a positive stress test but no obstruc-
tive CAD [90]. In addition to the medications discussed, life-
style changes such as exercise have significant benefit for
symptoms of chest pain [91]. Weight loss, smoking cessation,
and the Mediterranean diet all have been shown to improve
endothelial function [87] and should be recommended for
appropriate patients. Women with female-specific ischemic
heart disease are thought to have enhanced pain sensitivity
which may respond to xanthine derivatives and tricyclic anti-
depressants. Lastly, other nonpharmacologic treatments have
shown some efficacy including cognitive-behavioral therapy,




Women with coronary artery disease report worse health re-
lated quality of life outcomes compared to men [92]. In addi-
tion, there remains a pattern of higher mortality and worse
cardiovascular outcomes in women with ischemic heart dis-
ease [93, 94]. This is partially attributed to the incomplete use
of secondary prevention treatment regimens for coronary ath-
erosclerosis which improve survival, reduce recurrent ische-
mic events, and improve quality of life [95].
There are also sex differences in invasive strategies during
an ACS presentation. Compared with men, women are at in-
creased risk of adverse outcomes after acute coronary syn-
drome as well as percutaneous coronary interventions [96,
97]. They are also at increased risk of bleeding from medical
Table 1 Treatment of ischemic heart disease
Epicardial coronary atherosclerosis
Medications Antiplatelet Agent Recommended for all patients with CAD unless contraindicated
ACE-I Recommended for all patients with left ventricular ejection fraction <40 % and in those
with hypertension, diabetes, or chronic kidney disease, unless contraindicated.
Beta blockers Therapy should be started and continued for 3 years in all patients with who have had
a myocardial infarction or acute coronary syndrome
Statin Statin therapy should be initiated in all patients with established CAD
Lifestyle changes BP Control Patients with blood pressure >140/90 mmHg should be treated with lifestyle changes
and medications
Smoking Cessation Complete cessation is recommended
Weight Management Goal BMI is 18.5 to 24.9 kg/m2
Physical Activity Recommendation is 30 min of moderate intensity activity at least 5 days a week
Other Influenza Vaccine Patients with cardiovascular disease should have an annual influenza vaccination.
Cardiac Rehabilitation Patients with the diagnosis of ACS, coronary artery bypass surgery or PCI, chronic
angina and/or PAD within the past year should be referred to a cardiovascular
rehabilitation program
Invasive Possible PCI or CABG
Vasospastic diseasea
Conservative Smoking Cessation, Calcium Channel Antagonists, Long-Acting Nitrates, Magnesium, Statin
Invasive Possible PCI or CABGb
Spontaneous coronary artery dissectiona
Conservative Medical management is similar to that used in ACS and secondary prevention of epicardial coronary atherosclerosisc
Invasive Possible PCI or CABGc
Microvascular dysfunction
Conservative Medical and lifestyle recommendations are similar to those for epicardial coronary atherosclerosis. Can also consider ranolazine
for ischemic symptoms or tricyclic antidepressants for hypersensitivity to pain seen in female-specific IHD.
CAD coronary artery disease, ACE-I angiotensin converting enzyme inhibitors, BP blood pressure, BMI body mass index, ACS acute coronary
syndrome, PCI percutaneous coronary intervention, PAD peripheral artery disease, CABG coronary artery bypass grafting
a No established guidelines
b Adapted from Coronary Artery Spasm A 2009 Update [81]
c Adapted from Spontaneous Coronary Artery Dissection [82]
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therapies used in acute coronary syndrome and the use of
femoral access for PCI [98, 99].
Microvascular Dysfunction
It was originally thought that women with nonobstructive dis-
ease had a benign prognosis [100]; however, we now know that
this is not the case. Some of the discrepancies in findings can be
attributed to patient selection and the heterogeneity of inclusion
criteria in studies.Womenwith proven ischemia but no obstruc-
tive coronary artery disease still have increased events com-
pared to asymptomatic women [101]. In fact, women with sta-
ble angina and nonobstructive CAD are three times more likely
than men to experience a cardiac event within the first year of
cardiac catheterization [102]. In those with ACS and
nonobstructive disease, there is a 2 % risk of death and MI at
30 days [103]. Within the WISE Study, a subset of women
without angiographic CAD but persistent symptoms underwent
magnetic resonance spectroscopy (MRS) to assess for myocar-
dial ischemia. Those women with no obstructive CAD and a
normal MRS had a 13 % vascular event rate in the following
3 years; whereas those with an abnormal MRS study had a
cardiovascular event rate of 43 % which was similar to the
reference WISE women with obstructive CAD (48 %) [104].
More research is needed to determine the best diagnostic testing
and treatment strategies for these women.
Conclusion/Future Directions
We have come a long way in the past 25 years since the US
National Institutes of Health (NIH) mandated the inclusion of
women in all NIH-sponsored research in 1990. However, we
are only beginning to scratch the surface in the understanding
of sex differences in the pathophysiology and treatment of
ischemic heart disease. There are important differences that
clinicians should be cognizant of as discussed in this article.
These differences impact our understanding of the disease,
diagnosis, and treatment. In the future, as we continue to re-
evaluate our known therapies based on sex, we will be able to
adjust our treatment strategies accordingly. There remain
many biologic, pathophysiologic, and diagnostic sex differ-
ences in ischemic heart disease that have yet to be clarified
and will require additional research.
Compliance with Ethics Guidelines
Conflict of Interest MSanghavi andMGulati both declare no conflicts
of interest.
Human and Animal Rights and Informed Consent All studies by M
Gulati involving animal and/or human subjects were performed after
approval by the appropriate institutional review boards. When required,
written informed consent was obtained from all participants.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1.•• Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha
MJ, et al. Heart disease and stroke statistics—2014 update: a re-
port from the American Heart Association. Circulation.
2014;129(3):e28–e292. Summarized the most up-to-date statis-
tics on cardiovascular disease incidence, prevalence, and out-
comes. As well as information regarding cardiovascular dis-
ease risk factors.
2. Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb
KJ. Twelve-year follow-up of American women’s awareness of
cardiovascular disease risk and barriers to heart health. Circ
Cardiovasc Qual Outcomes. 2010;3(2):120–7.
3. Ford ES, Capewell S. Coronary heart disease mortality among
young adults in the U.S. from 1980 through 2002: concealed
leveling of mortality rates. J Am Coll Cardiol. 2007;50(22):
2128–32.
4. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart
disease: evolving knowledge. J Am Coll Cardiol. 2009;54(17):
1561–75.
5. Kemp Jr HG, Vokonas PS, Cohn PF, Gorlin R. The anginal syn-
drome associated with normal coronary arteriograms. Report of a
six year experience. Am J Med. 1973;54(6):735–42.
6. DiamondGA, Forrester JS. Analysis of probability as an aid in the
clinical diagnosis of coronary-artery disease. N Engl J Med.
1979;300(24):1350–8.
7. McSweeney JC, Cody M, O’Sullivan P, Elberson K, Moser DK,
Garvin BJ.Women’s earlywarning symptoms of acutemyocardial
infarction. Circulation. 2003;108(21):2619–23.
8. Canto JG, Goldberg RJ, HandMM, Bonow RO, Sopko G, Pepine
CJ, et al. Symptom presentation of women with acute coronary
syndromes: myth vs reality. Arch Intern Med. 2007;167(22):
2405–13.
9. Kreatsoulas C, Shannon HS, Giacomini M, Velianou JL, Anand
SS. Reconstructing angina: cardiac symptoms are the same in
women and men. JAMA Intern Med. 2013;173(9):829–31.
10. Hemingway H, Langenberg C, Damant J, Frost C, Pyorala K,
Barrett-Connor E. Prevalence of angina in women versus men: a
systematic review and meta-analysis of international variations
across 31 countries. Circulation. 2008;117(12):1526–36.
11. Sharaf BL, Pepine CJ, Kerensky RA, Reis SE, Reichek N, Rogers
WJ, et al. Detailed angiographic analysis of womenwith suspected
ischemic chest pain (pilot phase data from the NHLBI-sponsored
Women’s Ischemia Syndrome Evaluation [WISE] Study
Angiographic Core Laboratory). Am J Cardiol. 2001;87(8):937–
41. A3.
12. Shaw LJ, Merz CN, Pepine CJ, Reis SE, Bittner V, Kip KE, et al.
The economic burden of angina in women with suspected ische-
mic heart disease: results from the National Institutes of Health–
National Heart, Lung, and Blood Institute–sponsored Women’s
34 Page 8 of 11 Curr Atheroscler Rep (2015) 17: 34
Ischemia Syndrome Evaluation. Circulation. 2006;114(9):894–
904.
13.• Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al.
Lifetime risks of cardiovascular disease. N Engl J Med.
2012;366(4):321–9. Emphasizes the importance of assessing
risk over the lifetime of a patient not just short term risk.
14. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey
SF, et al. Insights from the NHLBI-sponsored Women’s Ischemia
Syndrome Evaluation (WISE) study part I: gender differences in
traditional and novel risk factors, symptom evaluation, and
gender-optimized diagnostic strategies. J Am Coll Cardiol.
2006;47(3s1):S4–S20.
15. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA,
Sowers MF, Sternfeld B, et al. Are changes in cardiovascular
disease risk factors in midlife women due to chronological aging
or to the menopausal transition? J Am Coll Cardiol. 2009;54(25):
2366–73.
16. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex dif-
ference in coronary heart disease mortality among patients with
type 2 diabetes mellitus: a meta-analysis. Arch Intern Med.
2002;162(15):1737–45.
17. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for
incident coronary heart disease in women compared with men: a
systematic review and meta-analysis of 64 cohorts including 858,
507 individuals and 28,203 coronary events. Diabetologia.
2014;57(8):1542–51.
18. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor
for cardiovascular disease independent of high-density lipoprotein
cholesterol level: a meta-analysis of population-based prospective
studies. J Cardiovasc Risk. 1996;3(2):213–9.
19. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK,
et al. Metabolic syndrome and risk of incident cardiovascular
events and death: a systematic review and meta-analysis of longi-
tudinal studies. J Am Coll Cardiol. 2007;49(4):403–14.
20. Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel
WB, et al. Impact of high-normal blood pressure on the risk of
cardiovascular disease. N Engl J Med. 2001;345(18):1291–7.
21. Huxley RR, Woodward M. Cigarette smoking as a risk factor for
coronary heart disease in women compared with men: a system-
atic review and meta-analysis of prospective cohort studies.
Lancet. 2011;378(9799):1297–305.
22.•• Chomistek AK, Chiuve SE, Eliassen AH, Mukamal KJ, Willett
WC, Rimm EB. Healthy lifestyle in the primordial prevention of
cardiovascular disease among young women. J Am Coll Cardiol.
2015;65(1):43–51. This study demonstrates that much of the
risk associated with cardiovascular disease can be attributed
to lifestyle choice. Bringing focus onto primordial prevention.
23. Brown WJ, Pavey T, Bauman AE. Comparing population attrib-
utable risks for heart disease across the adult lifespan in women.
Br J Sports Med. 2014.
24. Kohli P, Gulati M. Exercise stress testing in women: going back to
the basics. Circulation. 2010;122(24):2570–80.
25. Mora S, Redberg RF, Cui Y, Whiteman MK, Flaws JA, Sharrett
AR, et al. Ability of exercise testing to predict cardiovascular and
all-cause death in asymptomatic women: a 20-year follow-up of
the lipid research clinics prevalence study. JAMA. 2003;290(12):
1600–7.
26. LadwigKH, Lederbogen F, Albus C, Angermann C, BorggrefeM,
Fischer D, et al. Position paper on the importance of psychosocial
factors in cardiology: update 2013. Ger Med Sci. 2014;12:Doc09.
27. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky
L. The epidemiology, pathophysiology, and management of psy-
chosocial risk factors in cardiac practice: the emerging field of
behavioral cardiology. J Am Coll Cardiol. 2005;45(5):637–51.
28. Parker G, Brotchie H. Gender differences in depression. Int Rev
Psychiatry. 2010;22(5):429–36.
29. LowCA, Thurston RC, Matthews KA. Psychosocial factors in the
development of heart disease in women: current research and fu-
ture directions. Psychosom Med. 2010;72(9):842–54.
30. Vaccarino V, Shah AJ, Rooks C, Ibeanu I, Nye JA, Pimple P, et al.
Sex differences in mental stress-induced myocardial ischemia in
young survivors of an acute myocardial infarction. Psychosom
Med. 2014;76(3):171–80.
31. Wong ND, Pio J, Valencia R, Thakal G. Distribution of C-reactive
protein and its relation to risk factors and coronary heart disease
risk estimation in the National Health and Nutrition Examination
Survey (NHANES) III. Prev Cardiol. 2001;4(3):109–14.
32. Karim R, Stanczyk FZ, Hodis HN, Cushman M, Lobo RA,
Hwang J, et al. Associations between markers of inflammation
and physiological and pharmacological levels of circulating sex
hormones in postmenopausal women. Menopause (New York,
NY). 2010;17(4):785–90.
33. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the
metabolic syndrome, and risk of incident cardiovascular events: an
8-year follow-up of 14 719 initially healthy American women.
Circulation. 2003;107(3):391–7.
34. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis
in patients with SLE—mechanisms and management. Nat Rev
Rheumatol. 2012;8(4):214–23.
35. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger Jr TA,
Jansen-McWilliams L, et al. Age-specific incidence rates of myo-
cardial infarction and angina in women with systemic lupus ery-
thematosus: comparison with the Framingham study. Am J
Epidemiol. 1997;145(5):408–15.
36. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS,
Wolfe MS, et al. Inhibition of coronary artery atherosclerosis by
17-beta estradiol in ovariectomized monkeys. Lack of an effect of
added progesterone. Arterioscler (Dallas, Tex). 1990;10(6):1051–
7.
37. Gerhard M, Ganz P. How do we explain the clinical benefits of
estrogen? From bedside to bench. Circulation. 1995;92(1):5–8.
38. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M,
HlatkyM, et al. Cardiovascular disease outcomes during 6.8 years
of hormone therapy: Heart and Estrogen/progestin Replacement
Study follow-up (HERS II). JAMA. 2002;288((1):49–57.
39. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ,
Kooperberg C, StefanickML, et al. Risks and benefits of estrogen
plus progestin in healthy postmenopausal women: principal re-
sults from the women’s health initiative randomized controlled
trial. JAMA. 2002;288(3):321–33.
40. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia
and risk of cardiovascular disease and cancer in later life: system-
atic review and meta-analysis. Br Med J (Clin Res Ed).
2007;335(7627):974.
41. Mannisto T, Mendola P, Vaarasmaki M, Jarvelin MR, Hartikainen
AL, Pouta A, et al. Elevated blood pressure in pregnancy and
subsequent chronic disease risk. Circulation. 2013;127(6):681–
90.
42. Parker DR, Lu B, Sands-Lincoln M, Kroenke CH, Lee CC,
O’Sullivan M, et al. Risk of cardiovascular disease among post-
menopausal women with prior pregnancy loss: the women’s
health initiative. Ann Fam Med. 2014;12(4):302–9.
43. Parikh NI, Cnattingius S, Dickman PW, Mittleman MA,
Ludvigsson JF, Ingelsson E. Parity and risk of later-life maternal
cardiovascular disease. Am Heart J. 2010;159(2):215–21 e6.
44. Udell JA, Lu H, Redelmeier DA. Long-term cardiovascular risk in
women prescribed fertility therapy. J Am Coll Cardiol.
2013;62(18):1704–12.
45. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose
tolerance, type 2 diabetes and metabolic syndrome in polycystic
ovary syndrome: a systematic review and meta-analysis. Hum
Reprod Update. 2010;16(4):347–63.
Curr Atheroscler Rep (2015) 17: 34 Page 9 of 11 34
46. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U,
Bronnum D, et al. Risk of ischemic heart disease in women after
radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–
98.
47.• Brenner DJ, Shuryak I, Jozsef G, Dewyngaert KJ, Formenti SC.
Risk and risk reduction of major coronary events associated with
contemporary breast radiotherapy. JAMA Intern Med.
2014;174(1):158–60. Discussion of the risk associated with ra-
diation therapy and ways to minimize risk.
48. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-
Jones DM, et al. Effectiveness-based guidelines for the prevention
of cardiovascular disease in women—2011 update: a guideline
from the American heart association. Circulation. 2011;123(11):
1243–62.
49. Dickerson JA, Nagaraja HN, Raman SV. Gender-related differ-
ences in coronary artery dimensions: a volumetric analysis. Clin
Cardiol. 2010;33(2):E44–9.
50. Kardys I, Vliegenthart R, Oudkerk M, Hofman A, Witteman JC.
The female advantage in cardiovascular disease: do vascular beds
contribute equally? Am J Epidemiol. 2007;166(4):403–12.
51. VaccarinoV, Badimon L, Corti R, deWit C, DorobantuM,Hall A,
et al. Ischaemic heart disease in women: are there sex differences
in pathophysiology and risk factors? Position paper from the
working group on coronary pathophysiology and microcirculation
of the European society of cardiology. Cardiovasc Res.
2011;90(1):9–17.
52. Dart AM, Du XJ, Kingwell BA. Gender, sex hormones and auto-
nomic nervous control of the cardiovascular system. Cardiovasc
Res. 2002;53(3):678–87.
53. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural
activation in visceral obesity. Circulation. 2002;106(20):2533–6.
54. Carney RM, Freedland KE, Veith RC. Depression, the autonomic
nervous system, and coronary heart disease. Psychosom Med.
2005;67 Suppl 1:S29–33.
55. Weiner DA, Ryan TJ, McCabe CH, Kennedy JW, Schloss M,
Tristani F, et al. Exercise stress testing. Correlations among history
of angina, ST-segment response and prevalence of coronary-artery
disease in the Coronary Artery Surgery Study (CASS). N Engl J
Med. 1979;301(5):230–5.
56. Gulati M, Shaw LJ, Bairey Merz CN. Myocardial ischemia in
women: lessons from the NHLBI WISE study. Clin Cardiol.
2012;35(3):141–8.
57. Camici PG, Crea F. Coronarymicrovascular dysfunction. N Engl J
Med. 2007;356(8):830–40.
58. Chokshi NP, Iqbal SN, Berger RL, Hochman JS, Feit F, Slater JN,
et al. Sex and race are associated with the absence of epicardial
coronary artery obstructive disease at angiography in patients with
acute coronary syndromes. Clin Cardiol. 2010;33(8):495–501.
59. Sharaf BL, Pepine CJ, Kerensky RA, Reis SE, Reichek N, Rogers
WJ, et al. Detailed angiographic analysis of women with
suspected ischemic chest pain (pilot phase data from the
NHLBI-sponsored Women’s Ischemia Syndrome Evaluation
[WISE] Study Angiographic Core Laboratory). Am J Cardiol.
2001;87(8):937–41. a3.
60. Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit
F, et al. Mechanisms of myocardial infarction in women without
angiographically obstructive coronary artery disease. Circulation.
2011;124(13):1414–25.
61. Farb A, Burke AP, Tang AL, Liang TY,Mannan P, Smialek J, et al.
Coronary plaque erosion without rupture into a lipid core. A fre-
quent cause of coronary thrombosis in sudden coronary death.
Circulation. 1996;93(7):1354–63.
62. Sun H, Mohri M, Shimokawa H, Usui M, Urakami L, Takeshita
A. Coronary microvascular spasm causes myocardial ischemia in
patients with vasospastic angina. J Am Coll Cardiol. 2002;39(5):
847–51.
63. Zaya M, Mehta PK, Merz CN. Provocative testing for coronary
reactivity and spasm. J Am Coll Cardiol. 2014;63(2):103–9.
64. Tweet MS, Hayes SN, Pitta SR, Simari RD, Lerman A, Lennon
RJ, et al. Clinical features, management, and prognosis of sponta-
neous coronary artery dissection. Circulation. 2012;126(5):579–
88.
65. Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL,
Reichek N, et al. Coronary microvascular dysfunction is highly
prevalent in women with chest pain in the absence of coronary
artery disease: results from the NHLBI WISE study. Am Heart J.
2001;141(5):735–41.
66. Patel SM, Lerman A, Lennon RJ, Prasad A. Impaired coronary
microvascular reactivity in women with apical ballooning syn-
drome (Takotsubo/stress cardiomyopathy). Eur Heart J Acute
Cardil Care. 2013;2(2):147–52.
67. Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch
JM, et al. Retinal arteriolar narrowing and risk of coronary heart
disease in men and women. The atherosclerosis risk in communi-
ties study. JAMA. 2002;287(9):1153–9.
68.•• Mieres JH, Gulati M, Bairey Merz N, Berman DS, Gerber TC,
Hayes SN, et al. Role of noninvasive testing in the clinical evalu-
ation of women with suspected ischemic heart disease: a consen-
sus statement from the American Heart Association. Circulation.
2014;130(4):350–79. Sex specific recommendations for nonin-
vasive testing for ischemic heart disease.
69. Alexander KP, Shaw LJ, Shaw LK, Delong ER, Mark DB,
Peterson ED. Value of exercise treadmill testing in women. J
Am Coll Cardiol. 1998;32(6):1657–64.
70. Gulati M, Black HR, Shaw LJ, Arnsdorf MF, Merz CN, Lauer
MS, et al. The prognostic value of a nomogram for exercise ca-
pacity in women. N Engl J Med. 2005;353(5):468–75.
71. Gulati M, Pandey DK, Arnsdorf MF, Lauderdale DS, Thisted RA,
Wicklund RH, et al. Exercise capacity and the risk of death in
women: the St James women take heart project. Circulation.
2003;108(13):1554–9.
72. Kothawade K, BaireyMerz CN.Microvascular coronary dysfunc-
tion in women: pathophysiology, diagnosis, and management.
Curr Probl Cardiol. 2011;36(8):291–318.
73. Shufelt CL, Thomson LE, Goykhman P, Agarwal M, Mehta PK,
Sedlak T, et al. Cardiac magnetic resonance imaging myocardial
perfusion reserve index assessment in women with microvascular
coronary dysfunction and reference controls. Cardiovascular diag-
nosis and therapy. 2013;3(3):153–60.
74. Panting JR, Gatehouse PD, Yang GZ, Grothues F, Firmin DN,
Collins P, et al. Abnormal subendocardial perfusion in cardiac
syndrome X detected by cardiovascular magnetic resonance im-
aging. N Engl J Med. 2002;346(25):1948–53.
75. Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in
hypertension treatment, drug utilization patterns, and blood pres-
sure control among US adults with hypertension: data from the
national health and nutrition examination survey 1999-2004. Am J
Hypertens. 2008;21(7):789–98.
76. Lewis WR, Ellrodt AG, Peterson E, Hernandez AF, LaBresh KA,
Cannon CP, et al. Trends in the use of evidence-based treatments
for coronary artery disease among women and the elderly: find-
ings from the get with the guidelines quality-improvement pro-
gram. Circ Cardiovasc Qual Outcomes. 2009;2(6):633–41.
77. Chou AF, Scholle SH, Weisman CS, Bierman AS, Correa-de-
Araujo R, Mosca L. Gender disparities in the quality of cardiovas-
cular disease care in private managed care plans. Womens Health
Issues. 2007;17(3):120–30.
78. Witt BJ, Jacobsen SJ, Weston SA, Killian JM, Meverden RA,
Allison TG, et al. Cardiac rehabilitation after myocardial infarc-
tion in the community. J Am Coll Cardiol. 2004;44(5):988–96.
79. Suaya JA, Shepard DS, Normand SL, Ades PA, Prottas J, Stason
WB. Use of cardiac rehabilitation by medicare beneficiaries after
34 Page 10 of 11 Curr Atheroscler Rep (2015) 17: 34
myocardial infarction or coronary bypass surgery. Circulation.
2007;116(15):1653–62.
80. Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman
MJ, et al. Sex-related differences of coronary atherosclerosis re-
gression following maximally intensive statin therapy: insights
from SATURN. JACC Cardiovasc Imaging. 2014.
81. Stern S, Bayes de Luna A. Coronary artery spasm: a 2009 update.
Circulation. 2009;119(18):2531–4.
82. Alfonso F, Paulo M, Lennie V, Dutary J, Bernardo E, Jimenez-
Quevedo P, et al. Spontaneous coronary artery dissection: long-
term follow-up of a large series of patients prospectively managed
with a Bconservative^ therapeutic strategy. JACC Cardiovasc
Interv. 2012;5(10):1062–70.
83. Tweet MS, Eleid MF, Best PJ, Lennon RJ, Lerman A, Rihal CS,
et al. Spontaneous coronary artery dissection: revascularization
versus conservative therapy. Circ Cardiovasc Interv. 2014;7(6):
777–86.
84. Maddox TM, Ho PM, Roe M, Dai D, Tsai TT, Rumsfeld JS.
Utilization of secondary prevention therapies in patients with
nonobstructive coronary artery disease identified during cardiac
catheterization: insights from the national cardiovascular data reg-
istry Cath-PCI registry. Circ Cardiovasc Qual Outcomes.
2010;3(6):632–41.
85. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG,
et al. Sex-related differences in the presentation, treatment and
outcomes among patients with acute coronary syndromes: the
global registry of acute coronary events. Heart. 2009;95(1):20–6.
86. Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus
amlodipine versus isosorbide-5-mononitrate on anginal symptoms
in syndrome X. Am J Cardiol. 1999;84(7):854–6. A8.
87. Agrawal S, Mehta PK, Bairey Merz CN. Cardiac syndrome X:
update 2014. Cardiol Clin. 2014;32(3):463–78.
88. Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensin-
converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl co-
enzyme A reductase in cardiac Syndrome X: role of superoxide
dismutase activity. Circulation. 2004;109(1):53–8.
89. Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH,
Soydan I. Benefits of statin treatment in cardiac syndrome-X1.
Eur Heart J. 2003;24(22):1999–2005.
90. Mehta PK, Goykhman P, Thomson LE, Shufelt C, Wei J, Yang Y,
et al. Ranolazine improves angina in women with evidence of
myocardial ischemia but no obstructive coronary artery disease.
JACC Cardiovasc Imaging. 2011;4(5):514–22.
91. Eriksson BE, Tyni-Lenne R, Svedenhag J, Hallin R, Jensen-
Urstad K, Jensen-Urstad M, et al. Physical training in syndrome
X: physical training counteracts deconditioning and pain in syn-
drome X. J Am Coll Cardiol. 2000;36(5):1619–25.
92. Norris CM, Ghali WA, Galbraith PD, Graham MM, Jensen LA,
Knudtson ML, et al. Women with coronary artery disease report
worse health-related quality of life outcomes compared to men.
Health Qual Life Outcomes. 2004;2:21.
93. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E,
Danchin N, et al. Gender differences in the management and clin-
ical outcome of stable angina. Circulation. 2006;113(4):490–8.
94. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF,
Maree AO, et al. Sex differences in medical care and early death
after acute myocardial infarction. Circulation. 2008;118(25):
2803–10.
95. Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA,
Franklin BA, et al. AHA/ACCF secondary prevention and risk
reduction therapy for patients with coronary and other atheroscle-
rotic vascular disease: 2011 update: a guideline from theAmerican
Heart Association and American College of Cardiology
Foundation. Circulation. 2011;124(22):2458–73.
96. Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD,
Van de Werf F, et al. Sex, clinical presentation, and outcome in
patients with acute coronary syndromes. Global use of strategies
to open occluded coronary arteries in acute coronary syndromes
IIb investigators. N Engl J Med. 1999;341(4):226–32.
97. Lansky AJ, Hochman JS,Ward PA,Mintz GS, Fabunmi R, Berger
PB, et al. Percutaneous coronary intervention and adjunctive phar-
macotherapy in women: a statement for healthcare professionals
from the American Heart Association. Circulation. 2005;111(7):
940–53.
98. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF,
Hochman JS, et al. Sex differences in major bleeding with glyco-
protein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid
risk stratification of Unstable angina patients Suppress ADverse
outcomes with Early implementation of the ACC/AHA guide-
lines) initiative. Circulation. 2006;114(13):1380–7.
99. Doyle BJ, Ting HH, Bell MR, Lennon RJ, Mathew V, Singh M,
et al. Major femoral bleeding complications after percutaneous
coronary intervention: incidence, predictors, and impact on long-
term survival among 17,901 patients treated at the Mayo Clinic
from 1994 to 2005. JACC Cardiovasc Interv. 2008;1(2):202–9.
100. Kemp HG, Kronmal RA, Vlietstra RE, Frye RL. Seven year sur-
vival of patients with normal or near normal coronary arterio-
grams: a CASS registry study. J Am Coll Cardiol. 1986;7(3):
479–83.
101. Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw
LJ, Handberg EM, et al. Adverse cardiovascular outcomes in
women with nonobstructive coronary artery disease: a report from
the women’s ischemia syndrome evaluation study and the St
James women take heart project. Arch Intern Med. 2009;169(9):
843–50.
102. Sedlak TL, Lee M, Izadnegahdar M, Merz CN, Gao M,
Humphries KH. Sex differences in clinical outcomes in patients
with stable angina and no obstructive coronary artery disease. Am
Heart J. 2013;166(1):38–44.
103. Kaski JC, Rosano GM, Collins P, Nihoyannopoulos P, Maseri A,
Poole-Wilson PA. Cardiac syndrome X: clinical characteristics
and left ventricular function. Long-term follow-up study. J Am
Coll Cardiol. 1995;25(4):807–14.
104. Johnson BD, Shaw LJ, Buchthal SD, Bairey Merz CN, Kim HW,
Scott KN, et al. Prognosis in women with myocardial ischemia in
the absence of obstructive coronary disease: results from the
National Institutes of Health-National Heart, Lung, and Blood
Institute-Sponsored Women’s Ischemia Syndrome Evaluation
(WISE). Circulation. 2004;109(24):2993–9.
105. Crea F, Camici PG, Bairey Merz CN. Coronary microvascular
dysfunction: an update. Eur Heart J. 2014;35(17):1101–11.
Curr Atheroscler Rep (2015) 17: 34 Page 11 of 11 34
